NL-OMON47682已完成不适用
Systemic bioavailability of enteral protein-bound versus free amino acid nutrition during intestinal protein malabsorption in critical illness - PANINI-trial
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 16 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1) Age > 18 and < 75 years
- •2) Faecal weight > 350g/day
- •3) Critical illness of any origin (e.g. medical, surgical, trauma) requiring admittance on ICU ward.
- •4) Expected ICU stay for the duration of the study protocol
- •5) Mechanically ventilated (PaO2/FiO2 ratio of >100 and <300)
- •6) Nasogastric tube in situ
- •7) Receiving full enteral nutrition without gastric residual volumes
- •8) Arterial (any location) line in situ
- •9) Flexi-seal system in situ
排除标准
- •1) Proven (pre-existing) intestinal disease that potentially limits normal gut function and absorption of nutrients (e.g. IBD, short-bowel, entero-cutaneous fistulas including a surgical enterostomy)
- •2) Proven (pre-existing) primary pancreatic disease or obstruction of the pancreatic duct of any origin (e.g. pancreatitis, carcinoma).
- •3) Patients who are moribund (not expected to be in ICU for more than 48 hours
- •due to imminent death)
- •4) A lack of commitment to full aggressive care during the first week due to severity of illness, comorbidities and potential harm from maximal treatment (anticipated withholding or withdrawing treatments)
- •5) Absolute contraindication to enteral nutrients (e.g., gastrointestinal [GI] perforation, obstruction or no GI tract access for any reason)
- •6) Receiving parenteral nutrition.
- •7) Nasoduodenal or nasojejunal feeding tube
- •8) Renal dysfunction defined as a serum creatinine >171 *mol/L or a urine output of less than 500 ml/last 24 hours
- •9) Patients requiring chronic veno-venous hemofiltration
- •10) Patients on ECMO/ELS
- •11) Cirrhosis * Child Pugh class C/D liver disease
- •12) Patients with primary admission diagnosis of burns (>30% body surface area)
- •13) Weight less than 50 kg or greater than 100 kg
- •14) Pregnant patients or lactating with the intent to breastfeed
- •15) Previous randomization in this study
- •16) Enrolment in any other interventional study
- •17) Milk/lactose allergy
- •18) Previous participation in a 13C amino acid tracer study within the last year
研究者
相似试验
已完成
2 期
Evaluation of the systemic bioavailability of gentamicin released from Herafill® Beads G and Garamycin® Schwamm in patients after hip-cup arthroplasty in aseptic revision of hip endoprothesis - A comparative, randomized monocentric studyASEPTICREVISIONOFHIPENDOPROTHESISDRKS00023902Heraeus Medical GmbH30
已完成
不适用
Bioavailability and metabolic effects in humans of n-3 polyunsaturated fatty acids and conjugated linoleic acid after consumption of naturally enriched cow milkutritionNutritional, Metabolic, EndocrineNutritionISRCTN16004121Feiraco Lacteos S.L. (Spain)38
尚未招募
1 期
TASK 011-RPT-Crush:Relative bioavailability of three generic rifapentine and isoniazid compounds when manipulated in adults with latent tuberculosis: a bridge to paediatric dosing needs (RPT CRUSH”)TuberculosisPACTR202306775627089Stellenbosch University24
尚未招募
不适用
Bioequivalence study of esomeprazole magnesium 10 mg sachetIRCT20130626013776N103Poursina Pharmaceuticals24
已完成
不适用
Folate Absorption Study in Healthy AdultsFolate status in healthy adultsDiet and Nutrition - Other diet and nutrition disordersACTRN12610000501044niversity of Otago16